This is not the first editorial in Clinical Chemistry dedicated to the testing of urine for cell-free DNA. In 2000 Lo (1 ) highlighted the findings of Botezatu et al. (2 ), who were the first to report the transfer of DNA across the kidney barrier into urine. The origins of detected transrenal DNA sequences were carcinomas, blood transfusions, and, in pregnant women, the fetus. After this first report, some pioneering work was done in transplant medicine. Urinary microchimerism was found in women transplant patients after they had received a kidney from a male donor (3, 4 ) . In a quantitative analysis it was demonstrated that transplantderived DNA was increased during graft rejection, indicating a potential marker for transplant control (4 ).
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Later, attempts were made to detect cell-free fetal DNA in maternal urine. Maternal urine analysis was fraught with technical difficulties, however, suggesting that the concentration of transrenal DNA might be too low for standard PCR protocols. On the basis of DNA isolation and amplification techniques some authors reported positive results (2, (5) (6) (7) , whereas others did not (4, 8, 9 ) . The reason for the differing outcomes was attributed to renal function, in particular glomerular permeability, small size of DNA fragments, and the presence of urinary nucleases. A comprehensive review covering many aspects of transrenal DNA was published by Umansky and Tomei (10 ) . It was reported that transrenal DNA appears in fragments of 150 -200 bp. Nearly a decade after the first report (2 ), another transformative report on this topic appears in this issue of Clinical Chemisty (11 ) . Interestingly, Melkonyan and Umansky are among the authors of both papers.
The current study, reported by Shekhtman et al. (11 ) , aimed at optimizing the molecular technique of transrenal DNA analysis in urine. In a first set of experiments the investigators used a novel DNA isolation and purification technique based on the adsorption of nucleic acids to Q-Sepharose resin, which allows isolation of short (150 -200 bp) and very short (50 -150 bp) DNA fragments. A comparison with the silica-based method showed that Q-Sepharose resin was superior in DNA detection, as demonstrated by a 100% detection rate with the Q-Sepharose resin method vs 70% with the silica method. Shekhtman et al. (11 ) designed another experiment to characterize fetal transrenal DNA. They performed real-time PCR using 4 sets of primers to amplify sequences of 25-88 bp within the sex determining region Y (SRY) gene. These experiments showed that the assay diagnostic sensitivity was inversely correlated with the length of the PCR targets. The use of a short amplicon size of 25 bp led to a tremendous increase in the detection of fetal DNA in maternal urine, whereas it was completely undetectable with 88-bp fragments. The experimental validation was followed by a clinical study on pregnant women. The results of 173 urine samples obtained from pregnant women revealed a positive predictive value of 87.6% and a negative predictive value of 95.2%. For urine samples collected in the first trimester the test showed 100% sensitivity and 100% specificity. A drawback of this study, as addressed by the authors, was that the tested urine samples were not freshly collected, but had been stored for 2 years, a condition that might have decreased the sensitivity. A potential problem with urine analysis is the possibility of contamination with male DNA, originating from sexual intercourse, leading to false-positive results. Some authors have introduced an additional centrifugation step before DNA isolation to avoid male contamination by sperm (7 ) .
The study reported by Shekhtman et al. (11 ) provides important insights into the molecular characteristics of transrenal DNA. Based on their new technical approach of DNA isolation and amplification, urine has become for the first time a potent body fluid for noninvasive DNA analysis. The protocol for optimized transrenal DNA analysis might pave the road to interesting future studies in prenatal diagnosis and oncology and transplant medicine. 
